Investors

Updates

  • Home
  • Investors
  • Updates
Investors
Updates
Entry into the Next-Generation Biopharmaceutical Business through Domestic Supply of ‘Protein A’
2012.11.05

Entry into Next-Generation Bio Business through Domestic Supply of ‘Protein A’

 

 

“Core material for biopharmaceutical manufacturing, diversification of domestic supply routes opened”

 

- Daehan New Pharm Co., Ltd. advances into the next-generation bio business with domestic supply of ‘Protein A’

- Contributing to enhancing the international competitiveness of domestic pharmaceutical companies’ biopharmaceutical development by reducing costs

- Breaking the exclusive supply structure and diversifying domestic supply of ‘Protein A’ through partnerships with Korea, US, China, and Japan

 

Daehan New Pharm Co., Ltd. (CEO Bae Kun-Woo), a mid-sized KOSDAQ-listed pharmaceutical company, announced strategic partnerships with companies in Korea, the US, China, and Japan to diversify the domestic supply of ‘Protein A,’ an essential core material for biopharmaceutical production.

 

With the expiration of patents on biopharmaceuticals, domestic companies accelerating biosimilar production can now escape the existing exclusive supply system and strengthen their international competitiveness in the biopharmaceutical field by reducing costs and improving research efficiency through diversified supply chains. Until now, domestic supply of ‘Protein A’ had been monopolized by GE (General Electric).

 

In the strategic partnership, Daehan New Pharm has signed supply agreements with GenScript (US) and Pharmawin Japan, where GenScript handles product manufacturing and technical support, and Pharmawin oversees Asian sales marketing and technical support services. Itochu Shanghai (China) acts as coordinator for entry into the Chinese market, sharing advanced market experience and systems.

 

The ‘Protein A’ supplied by Daehan New Pharm plays a crucial role in determining efficiency, time, cost, and purity in biopharmaceutical manufacturing. Korean companies, research institutes, and universities use ‘Protein A’ extensively in purification processes, with annual usage expected to exceed 5,000 liters, roughly worth 60 billion KRW.

 

Major domestic biopharmaceutical companies include Celltrion, Samsung Biologics, LG Life Sciences, Hanwha Chemical, AProgen, HanAll BioPharma, Hanmi Pharmaceutical, and Green Cross, all anticipated to replace ‘Protein A’ every six months.

 

Daehan New Pharm plans to expand its product portfolio through continuous technological partnerships and supply essential products for biopharmaceutical production in Korea, with future technology transfer expected to support market growth.

 

CEO Bae Kun-Woo said, “The agreement includes mutual cooperation among four countries to continuously enhance Daehan New Pharm’s involvement in bio products and services and provide total solutions for biopharmaceutical processes. Daehan New Pharm holds the Korean market rights for ‘Protein A’ and will serve as a joint partner in expanding into the Asian market.”

 

GenScript co-founder Dr. Luquan Wang and Pharmawin chairman Mr. Okamoto, participants in the signing ceremony, stated, “Discussions with Daehan New Pharm began early, and the agreement process has proceeded smoothly based on trust and cooperation. All four participating companies recognize their mutual importance and are determined to collaboratively pioneer the biopharmaceutical market.”

 

Founded in 1984, Daehan New Pharm is a research and development-focused mid-sized pharmaceutical company that develops and produces a diverse range of products from specialty pharmaceuticals to obesity solutions, veterinary medicines, and genetic development. Since its KOSDAQ registration in 2002, it has moved toward specialized affiliated industries and entered the bio business to become a global pharmaceutical hidden champion aiming to create a comprehensive health and welfare company (Pharmatopia) for a healthy and happy life.

 

■ Reference: Bio Business Market Outlook

The global pharmaceutical market is approximately $769.7 billion, with biopharmaceuticals accounting for about $104.6 billion, approximately 13.6% of the total market. Biopharmaceuticals are rapidly growing at an average annual rate of about 17.3%, expected to exceed $160 billion in 2013 and account for over 30% of the total pharmaceutical market.

 

Korea’s biopharmaceutical growth is also highly regarded abroad. The respected US RAND Institute projected that Korea’s biopharmaceutical technology would reach 95% of the US level by 2020 and predicted growth to 15 trillion KRW within seven years.

 

Biopharmaceuticals are categorized as bio originals, biosimilars, and biobetters. Biosimilars are generic protein antibody drugs with verified safety and efficacy, requiring significantly lower R&D costs and shorter development times than new drug development. Since 2012, numerous blockbuster protein drug patents have expired, with 21 blockbuster protein drugs expiring over three years, generating about $73.9 billion in revenue.

 

Biobetters improve upon original biopharmaceuticals by enhancing efficacy and reducing side effects. They are considered second-generation biopharmaceuticals following biosimilars. Biobetter development is ongoing in Korea, Japan, China, the US, and Europe, with the market expected to grow to approximately $400 billion by 2020.
List
Article 1 (Purpose)
These Terms and Conditions are intended to define the terms of use, rights, obligations, and responsibilities between Daehan Nupharm Co., Ltd. (hereinafter the “Company”) and users regarding all websites operated by the Company (hereinafter the “Site”) and any online contents provided through the Site (hereinafter the “Contents”).
Article 2 (Effect and Amendment of the Terms)
1. These Terms shall apply to all users (including job applicants) who wish to use the Site and its Contents, as stated at the bottom of the Site.
2. Users who access the Site or register by giving consent shall be deemed to have agreed to these Terms.
3. The Company may amend these Terms to the extent that such changes do not violate relevant laws including the Act on the Regulation of Terms and Conditions. Any amended Terms shall take effect upon notice through the Site.
4. Continued use of the Site or the Contents after such notice shall be deemed acceptance of the revised Terms.
Article 3 (Matters Not Specified in the Terms)
Any matters not specified herein shall be governed by relevant laws and regulations.
Article 4 (Obligations)
Obligations of the Company
The Site shall maintain the confidentiality of users’ personal information and use it solely for purposes within the Site, such as improving and operating services or providing new information. It shall not be transferred to any third party for any other purpose. (However, exceptions shall be made where disclosure is legally required—for example, upon a lawful request by investigative authorities or the Korea Communications Standards Commission.)

Obligations of Users and Job Applicants
1. Users must comply with these Terms, applicable laws, and all notices posted on the Site.
2. Users may not engage in profit-seeking activities using the information or Contents without prior consent from the Company. That is, information or Contents obtained from the Site may not be reproduced, modified, published, or broadcast without the Company’s prior approval.
3. Users must not alter or distribute information or Contents provided by the Site in any manner that violates public order or decency
4. Users must not infringe any intellectual property rights, including copyrights, without the Company’s consent, nor harm the reputation of the Site or third parties, or interfere with their business.
Article 5 (Service Availability)
The Site shall, in principle, be available year-round without interruption, except in cases of business or technical difficulties or other unavoidable circumstances. However, the Company may partially or fully restrict service when necessary—such as for maintenance, system failure, or service overload caused by force majeure.
Article 6 (Provision, Restriction, and Suspension of Information)
1. The administrator may, in the course of operating the Site, provide various information through channels other than the Site itself.
2. The Company may restrict or suspend service when it becomes impossible to continue providing it.
Article 7 (Disclaimer)
1. The Company shall not be liable for any failure to operate the Site or provide Contents due to policy changes, special circumstances, or force majeure.
2. The Company shall not be liable for any service interruptions or restrictions arising from causes attributable to the user.
3. The Company shall not be responsible for information posted by users; all responsibility lies with the user.
4. The Company shall not be liable for any disputes or issues between users and third parties arising through the Site.
5. The Company shall not be liable for any damages caused by the intentional acts or negligence of users or visitors arising from the Site or its Contents.
6. The Company shall not be responsible for users’ failure to gain expected benefits from the service, or for any damages resulting from their choice or use of service materials.
Article 8 (Compensation for Damages)
The Company shall not be liable for any damages incurred by users in connection with the use of the Site or its Contents.
Article 9 (Governing Law and Jurisdiction)
Any disputes or lawsuits arising between the Company and users in relation to the use of the Site and its Contents shall be subject to the jurisdiction of the court having authority over the location of the Company’s head office, and the governing law shall be the laws of the Republic of Korea.
Daehan Nupharm Co., Ltd. (hereinafter referred to as the “Company”) values customers’ personal information and complies with the Act on Promotion of Information and Communications Network Utilization and Information Protection, etc.
Through this Privacy Policy, the Company informs you of how and for what purposes your personal information is used,
and what measures are being taken to protect your personal data.
In the event of any amendments to this Privacy Policy, the Company will notify users through website announcements (hereinafter referred to as the “Site”) or individual notices.
This policy has been effective since January 1, 2014.
Items of Personal Information Collected
The Company collects the following personal information for purposes such as job applications, consultations, inquiries, and service requests.

Collected items: name, date of birth, gender, phone number (mobile/landline), address, email, photo, educational background, occupation, career details, company name, department, position, period of employment, educational history, career history, salary, job description, projects undertaken, detailed work tasks, major achievements, reason for resignation, qualifications, family information, self-introduction, veteran status, disability status, and any personal information submitted by the user for recruitment purposes. Additionally, during service use or business processing, the following information may be automatically generated and collected:
Type of browser and operating system, visit records (IP address, access time), and cookies.
Method of collection: through the Site (general inquiries, product inquiries, partnership proposals, recruitment).
Purpose of Collecting and Using Personal Information
The Company utilizes the collected personal information for the following purposes:
Responding to various inquiries.
User management and handling of complaints or civil petitions.
Evaluation and processing of recruitment applications.
Retention and Use Period of Personal Information
In principle, personal information is destroyed without delay once the purpose of collection and use has been fulfilled.
However, if retention is required under relevant laws and regulations, the Company may retain user information for a specific period as prescribed by such laws.
Items retained: Personal information items specified above.
Legal basis for retention: Consumer protection and data management.
Retention period: 3 years.
Records related to consumer complaints or dispute resolution: 3 years (in accordance with the Act on the Consumer Protection in Electronic Commerce, etc.)
Procedures and Methods of Personal Information Destruction
In principle, the Company promptly destroys personal information once the purpose of collection and use has been achieved. The procedures and methods of destruction are as follows:
Destruction procedures: Information entered by users for purposes such as membership or application submission is transferred to a separate database (or stored separately in paper form) after the purpose has been achieved. It is retained for a certain period in accordance with internal policies and relevant laws (refer to retention and use period), and then destroyed. Personal information transferred to a separate database is not used for any purpose other than as required by law.
Destruction method: The data is deleted using a database deletion method.
Provision of Personal Information
The Company does not, in principle,
When users have given prior consent.
When required by law or when an investigative agency requests such information in accordance with legally prescribed procedures.
Entrustment of Collected Personal Information
The Company does not entrust users’ personal information to external companies without prior consent.
Should such entrustment become necessary in the future, the Company will notify users of the entrusted party and the scope of the entrusted tasks, and obtain prior consent when required.
Rights of Users and Legal Representatives, and Exercise Thereof
Users may, at any time, view or modify their registered personal information and may also request withdrawal of membership.
If you contact the Personal Information Manager in writing, by phone, or via e-mail, the Company will take prompt action.
When you request correction of an error in your personal information, the Company will not use or provide such information until the correction has been completed.
If incorrect information has already been provided to a third party, the Company will notify the third party of the correction without delay so that it may be applied.
Personal information that has been canceled or deleted at the user’s request is handled according to the “Retention and Use Period of Personal Information” policy and will not be viewed or used for any other purpose.
For users under the age of 14, their legal representative has the right to access or correct the child’s personal information and to withdraw consent to its collection and use.
Use of Cookies
Purpose of Using Cookies
Cookies are used to prevent duplicate display of pop-up notifications.
Installation, Operation, and Rejection of Cookies
Users have the option to accept or reject the installation of cookies. Accordingly, users can set their web browser options to allow all cookies, to confirm each time a cookie is stored, or to reject all cookies.
By adjusting the settings of the web browser in use, users may allow all cookies, be prompted to confirm each time a cookie is saved, or refuse the storage of all cookies.
Example of setting method (for Internet Explorer): Tools at the top of the web browser → Internet Options → Privacy tab.
Personal Information Complaint and Inquiry Service
To protect customers’ personal information and handle related complaints, the Company designates the following department and Personal Information Manager
Customer Service Department: IT Team, Management Information Division
Personal Information Manager: Park Kangwon
Phone No.: +82-31-778-2626
Email: webmaster@dhnp.co.kr

You may contact the Personal Information Manager or the responsible department regarding any inquiries or complaints related to personal information protection arising from the use of the Company’s services.
The Company will provide prompt and adequate responses to your inquiries.
For further reports or consultations concerning personal data infringement, please contact the following organizations:

1. Personal Information Infringement Report Center (www.1336.or.kr/ No area code 118)
2. Korea Internet & Security Agency, Privacy Mark Certification Committee (www.eprivacy.or.kr/+82-2-580-0533–4)
3. Supreme Prosecutors’ Office Cyber Crime Investigation Center (http://icic.sppo.go.kr/+82-2-3480-3600)
4. National Police Agency Cyber Terror Response Center (www.ctrc.go.kr/+82-2-392-0330)